Related Experiment Video
Updated: Apr 30, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.7K
Management challenges in a child with hyperinsulinemic hypoglycemia.
Deepti Chaturvedi1, Rajesh Khadgawat1, Jeyaraman Kanakamani1
1Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India.
Summary
Malignant insulinoma, a rare pediatric cancer, was diagnosed in an 18-month-old child with islet cell hyperplasia. Despite surgical interventions, the child developed metastatic disease, representing the youngest reported case.
Area of Science:
- Pediatric Oncology
- Endocrinology
- Surgical Gastroenterology
Background:
- Malignant insulinoma is an exceptionally rare tumor in pediatric populations.
- Hyperinsulinemic hypoglycemia in infants can be caused by various conditions, including rare pancreatic tumors.
Purpose of the Study:
- To report the youngest known case of malignant insulinoma with metastatic disease in a child.
- To highlight the diagnostic and management challenges of pediatric malignant insulinoma.
Main Methods:
- Case presentation of an 18-month-old child with recurrent hyperinsulinemic hypoglycemia.
- Diagnostic imaging including Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scan.
- Surgical management (enucleation and subtotal pancreatectomy) and histopathological confirmation with immunostaining.
Main Results:
- The patient presented with hyperinsulinemic hypoglycemia, initially treated with tumor enucleation and later subtotal pancreatectomy.
- Despite surgical interventions, metastatic insulinoma to the liver was confirmed.
- This case represents the youngest reported instance of metastatic malignant insulinoma in a child.
Conclusions:
- Malignant insulinoma, though rare, should be considered in pediatric cases of persistent hyperinsulinemic hypoglycemia.
- Early and accurate diagnosis, coupled with aggressive management, is crucial for pediatric patients with malignant insulinoma.
- Metastatic potential underscores the need for vigilant monitoring and advanced imaging in affected children.
More Related Videos
Related Concept Videos
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Hypoglycemia
30
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30
Hyperglycemia
25
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Diabetes Mellitus: Type 2 and Gestational
4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K

